Heves Varmegyei Markhot Ferenc Oktatokorhaz Es Rendelointezet — Clinical Trial Site

54 Registered trials

21 Currently recruiting

Organisation

Heves Varmegyei Markhot Ferenc Oktatokorhaz Es Rendelointezet

Location

Eger, Hungary

Identifier

ORG-100040734

Address

Knezich Karoly Utca 1, 3300, Hungary

Departments

#2087: Belgyogyaszati Centrum
2027; Csecsemő, Gyermekgyógyászati és Neonatológiai osztály
2505: Szemeszeti Osztaly
2701: Belgyógyászati-Infektológiai Centrum - BIC Belgyógyászati Osztály
4008:Reumatológiai Osztály
Belgyógyászat
Belgyógyászat - Infektológiai Centrum
Belgyogyaszati Infektologiai Centrum, Belgyogyaszati Osztaly
Belgyógyászati Osztály
Belgyógyászati- és Infektológiai Centrum
Belgyogyaszati-Infektologiai Centrum
Belgyogyaszati-Infektologiai Centrum - BIC Belgyogyaszati Osztaly
Belgyógyászati-Infektológiai Centrum – BIC Belgyógyászati Osztály
Belgyogyaszati-Infektologiai Centrum Belgyogyaszati Osztaly
Belgyógyászati-Infektológiai Centrum Infektológiai Osztály
Belgyógyászati-Infektológiai Centrum, Gasztroenterológiai Részleg
Cardiology
Center for Internal Medicine and Infectology, BIC
Csecsemő, Gyermekgyógyászati és Neonatológiai osztály
D
Department of General and Vascular Surgery
Department of Internal Medicine
Department of Internal Medicine - Gastroenterology
Department of Internal Medicine and Infectology
Department of Oncology
Department of Surgery and Vascular Surgery
Department of Urology
Hematology
III. Belosztaly
Internal Medicine Clinic
Internal Medicine- Infectology Centre
Kardiologiai Osztaly
n.a.
N/A
Neurológiai és Stroke osztály
Onkologiai Osztaly
Onkológiai Osztály és Ambulancia
Ophthalmology
Reumatológiai Osztály
Sebészeti és Érsebészeti osztály
Urológiai Osztály

Clinical trials at this site (54)

Search interface

A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown

2025-523766-25-00 Ulcerative colitis 5
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending

2025-521037-86-00 Immune system diseases 5
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti… Pending

2025-521038-27-00 Immune system diseases 5
A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative co… Pending

2025-522511-42-00 Crohn's disease 4
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting

2024-518296-56-00 Crohn’s Disease 5 2025-09-29
Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures Recruiting

2024-514499-42-00 Refractory Partial Onset Epilepsy 5 2025-03-12
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a… Recruiting

2023-509606-30-00 Ulcerative colitis 5 2024-07-24
A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared … Recruiting

2022-500257-16-00 Diabetic Foot Infections 5 2023-03-17
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting

2025-521036-11-00 Immune system disseases 5 2026-03-23
Prevention of Recurrent C. difficile Infection Study with AZD5148 Monoclonal Antibody Recruiting

2025-521416-19-00 Recurrence of Clostridioides difficile Infection 4 2026-03-12
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting

2025-521035-37-00 Immune system diseases 5 2026-03-02
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting

2025-521381-10-00 Moderately to Severely Active Ulcerative Colitis 5 2025-12-03
A clinical study of V940 and BCG in people with bladder cancer (V940-011) Recruiting

2024-517335-46-00 Bladder cancer 4 2025-06-05
A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti… Recruiting

2024-513053-69-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease. Recruiting

2024-512633-32-00 Crohn's disease 4 2025-04-07
Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting

2024-513853-66-00 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or 5 2025-02-04
Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc… Recruiting

2024-513852-13-00 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic 5 2025-01-20
A Phase 2/3 study to evaluate safety and efficacy of the combination of Bel- CHOP/ Fol-COP drugs against CHOP in newly diagnosed Peripheral … Recruiting

2023-507803-76-00 Peripheral T-Cell Lymphoma 10 2024-09-26
A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting

2023-508158-24-00 Moderately to Severely Active Crohn’s Disease 4 2024-06-25
Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy… Recruiting

2022-500531-36-00 Type 1 diabetes mellitus 4 2024-02-02
A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics o… Recruiting

2022-502193-16-00 Chronic lymphocytic leukemia, Multiple Myeloma and Non- 5 2023-11-14
A study to assess efficacy of citicoline on visual field preservation in patients with glaucoma Recruiting

2022-502273-42-00 Glaucoma 5 2023-11-08
Asciminib Roll-over Study Recruiting

2023-507557-16-00 chronic myelogenous leukemia (CML) or Philadelphia Chro 5 2022-08-31